ライフサイエンスコーパス: attenuated vaccine

1 r protection and support advancement of this attenuated vaccine.

2 eltawzy, was created and evaluated as a live attenuated vaccine.

3 lly serve as a positive-marker modified live-attenuated vaccine.

4 ed vaccine as compared with those given live attenuated vaccine.

5 for rational design of a genetically stable attenuated vaccine.

6 ccine and 36% (95% CI, 0 to 59) for the live attenuated vaccine.

7 that the M2KO virus has potential as a live attenuated vaccine.

8 ants (median age, 11 weeks) administered the attenuated vaccine.

9 hat can be used in the development of a live attenuated vaccine.

10 9% (95% CI, -113 to 33; P=0.55) for the live attenuated vaccine.

11 ed for the inactivated vaccines and the live attenuated vaccine.

12 at it may serve as the starting point for an attenuated vaccine.

13 formation to take steps toward developing an attenuated vaccine.

14 a safe and potentially more efficacious live attenuated vaccine.

15 pism of a virus is a new approach for a live attenuated vaccine.

16 o and supports targeting the SH gene in live attenuated vaccines.

17 s are good candidates for the design of live attenuated vaccines.

18 ILTV vaccines are less efficacious than live attenuated vaccines.

19 y attenuate hMPV for the development of live attenuated vaccines.

20 aramyxoviruses for rationally designing live attenuated vaccines.

21 hich combines the advantages of DNA and live attenuated vaccines.

22 t can be mutated to generate successful live attenuated vaccines.

23 culture has hindered the development of live-attenuated vaccines.

24 ines but not in children who received highly attenuated vaccines.

25 ontribute to virulence, and could be used as attenuated vaccines.

26 serve as a model for the rational design of attenuated vaccines.

27 tic deletion to produce whole parasite-based attenuated vaccines.

28 that induced by live virus and possibly live attenuated vaccines.

29 ors, and may differ for inactivated and live attenuated vaccines.

30 with vhs deleted have been proposed as live-attenuated vaccines.

31 f non-toxigenic C. difficile strains as live attenuated vaccines.

32 r approach for prevention is the use of live attenuated vaccines.

33 inactivated vaccines and cold-adapted, live attenuated vaccines.

34 or development of classical swine fever live attenuated vaccines.

35 e pathogenesis of HAV and the development of attenuated vaccines.

36 poor or diminished efficacy compared to live attenuated vaccines.

37 iviral discovery and development of new live attenuated vaccines.

38 erstand virus biology and develop novel live attenuated vaccines.

39 d activity is a strategy for generating live-attenuated vaccines.

40 imals (DIVA tests) for established killed or attenuated vaccines.

41 ay be more informative on the safety of live-attenuated vaccines.

42 on as safe, immunogenic, and protective live-attenuated vaccines.

43 r receipt of dose 1 among recipients of live attenuated vaccine (3.8%) than among recipients of inact

44 We propose that this live attenuated vaccine acts like a silent natural infection

45 Immunization with live, attenuated vaccine (administered intranasally) is not cu

46 We studied respiratory delivery of an attenuated vaccine against Blastomyces dermatitidis.

47 tential strategy to develop a neurovirulence-attenuated vaccine against chickenpox and herpes zoster

48 implications for developing a modified live-attenuated vaccine against HEV.

49 most promising candidates for a genetically attenuated vaccine against malaria (5) , as a unique and

50 ned F. novicida mutant (DeltaiglC) as a live attenuated vaccine against subsequent intranasal challen

51 ted mainly to reduced protection of the live attenuated vaccine against type B viruses.

52 e possibilities for developing improved live attenuated vaccines against arteriviruses and other viru

53 ons for development of both subunit and live-attenuated vaccines against ETEC and other enteric patho

54 ral infection and strategies to develop live attenuated vaccines against flaviviral species.IMPORTANC

55 eficient chlamydial strains function as live attenuated vaccines against genital and ocular infection

56 oplasmic tail mutants have potential as live attenuated vaccines against H5N1 influenza viruses.

57 feasibility of using M2 tail mutants as live attenuated vaccines against H5N1 virus.

58 imilar approach may guide the design of live-attenuated vaccines against Lassa and other arenaviral h

59 dy may aid in the design of efficacious live attenuated vaccines against PEDV, as well as other CoVs

60 the polymerase could be used to design live attenuated vaccines against serious pathogens within the

61 erapeutics and the development of killed and attenuated vaccines against this important emerging path

62 At least 14 different live attenuated vaccines against this pathogen are available

63 ) and Card9(-/-) mice immunized with a live, attenuated vaccine also fail to acquire protective immun

64 The live attenuated vaccine also prevented influenza illnesses bu

65 However, live attenuated vaccines also induce strong CD8 T cell respon

66 Among live attenuated vaccine and placebo recipients, cases were le

67 lity control of new lots of the current live-attenuated vaccine and provide insight for the rational

68 e a novel target for rational design of live attenuated vaccines and antiviral drugs.

69 the development of rationally-designed live-attenuated vaccines and antivirals for control of outbre

70 ebo-controlled trial of inactivated and live attenuated vaccines and compared titers in subjects with

71 s display characteristics desirable for live attenuated vaccines and hold potential as vaccine candid

72 r mucosal application in humans, use of live-attenuated vaccines and microbial vectors, and productio

73 diate this process will aid in the design of attenuated vaccines and of novel therapeutics.

74 association between revaccination with live attenuated vaccines and off-target infections are needed

75 uperseded by a final report, studies of live-attenuated vaccine, and studies of prepandemic seasonal

76 responses similar to those elicited by live-attenuated vaccines, and its flexibility permits the fas

77 ebo-controlled trial of inactivated and live attenuated vaccines, and we evaluated the laboratory end

78 Live attenuated vaccines appear to be the most effective in c

79 ine appeared to be efficacious, whereas live attenuated vaccine appeared to be less so.

80 However, the live-attenuated vaccine approach faces formidable obstacles,

81 Novel live attenuated vaccines are being developed that promise gre

82 Live attenuated vaccines are commonly used in the poultry ind

83 Live attenuated vaccines are considered the most viable vacci

84 nd the potential to develop multivalent live-attenuated vaccines are discussed.

85 Live attenuated vaccines are more immunogenic and have the ca

86 Live attenuated vaccines are traditionally generated by seria

87 ge to lentiviral vaccine immunity, even when attenuated vaccines are used that, to date, achieve the

88 ay serve as a novel approach to develop live attenuated vaccines as well as antiviral drugs for pneum

89 The superior efficacy of live attenuated vaccine, as compared with inactivated vaccine

90 y can lead to the development of novel, live attenuated vaccines, as well as antiviral drugs for pneu

91 irway selectively recruited airway Tregs and attenuated vaccine-augmented disease, reducing weight lo

92 D vaccine is one of the most successful live attenuated vaccines available.

93 rulence factors, we hypothesized that a live-attenuated vaccine based on PA14 might elicit a broader

94 nstrated the feasibility of creating defined attenuated vaccines based on a type A strain.

95 deration should be taken when designing live attenuated vaccines based on deletions of nonstructural

96 venue for the development of arenavirus live attenuated vaccines based on rearrangement of their vira

97 ed drastically following the introduction of attenuated vaccines, but progress toward the eradication

98 A single inoculation of the RVF MP-12 live attenuated vaccine by the aerosol or intranasal route ma

99 The fact that uncontrolled replication of an attenuated vaccine can lead to regaining of its virulenc

100 Although live attenuated vaccines can provide potent protection agains

101 f the p27 gene could be considered as a live attenuated vaccine candidate against visceral leishmania

102 Thus, ML29 is a promising attenuated vaccine candidate for Lassa fever.

103 is not available, and the more advanced live attenuated vaccine candidate in clinical trials requires

104 was then assessed for its efficacy as a live attenuated vaccine candidate in mice after challenge wit

105 Currently, the most promising live-attenuated vaccine candidate is a temperature-sensitive

106 The attenuated vaccine candidate is expected to be safe and

107 To control TMUV infection, a live-attenuated vaccine candidate of TMUV was developed in ou

108 Here we report on a live-attenuated vaccine candidate that contains a 10-nucleoti

109 ike HEp-2 cells, in which wild-type and live-attenuated vaccine candidate viruses grow equally well,

110 suggesting its potential as the basis of an attenuated vaccine candidate.

111 elA DeltaspoT mutant may be a promising live-attenuated vaccine candidate.

112 In our research, we developed novel live attenuated vaccine candidates against chikungunya virus

113 y of a CD-based approach for developing live-attenuated vaccine candidates against human-pathogenic a

114 viruses might have a great potential as live attenuated vaccine candidates against SIV infections of

115 onal development of safe and protective live attenuated vaccine candidates based on genome reorganiza

116 We therefore generated 2 live-attenuated vaccine candidates based on the insertion of

117 f the virus, many of which were developed as attenuated vaccine candidates by serial passage in fibro

118 and provides an approach for generating live-attenuated vaccine candidates for emerging coronaviruses

119 t also will lead to the development new live attenuated vaccine candidates for hMPV.

120 information for the rational design of live attenuated vaccine candidates for other viral hemorrhagi

121 tion as a target for rational design of live attenuated vaccine candidates for RSV and perhaps other

122 be assembled and have been developed as live attenuated vaccine candidates for several flaviviruses.

123 o-recover RV strains such as low-replicating attenuated vaccine candidates or low-cell culture passag

124 ential for further development as novel live attenuated vaccine candidates that may rapidly control d

125 s strategy may be useful for generating live attenuated vaccine candidates that prevent disease and f

126 fely attenuate FMDV and further develop live attenuated vaccine candidates to control such a feared l

127 genicity, justifying their inclusion in live attenuated vaccine candidates to protect against the cur

128 deISGylase activity for development of live attenuated vaccine candidates, and ISG15 as a novel biot

129 testing the potential of the three forms as attenuated vaccine candidates, strain 4295 was inoculate

130 d form the basis of a new generation of live attenuated vaccine candidates.

131 f this strain to evaluate the safety of live attenuated vaccine candidates.

132 scape mutants and mutations observed in live-attenuated vaccine candidates.

133 ype recombinant RSV, supporting their use as attenuated vaccine candidates.

134 s but suboptimal substitutions provides live attenuated vaccine candidates.

135 D can be used for the development of stable, attenuated vaccine candidates.

136 The current live attenuated vaccines (chicken embryo origin [CEO] and tis

137 The reference attenuated vaccine combined with these variant Env chall

138 nogenicity and protective efficacy of a live attenuated vaccine consisting of a recombinant severe ac

139 xed viral populations and indicate that live-attenuated vaccines containing virulent virus may be saf

140 needed of the host response to HRSV and its attenuated vaccine derivatives.

141 s lower respiratory tract and bear upon live attenuated vaccine development.

142 o the development of safe and effective live attenuated vaccines directed against VEEV and other rela

143 o the development of safe and effective live attenuated vaccines directed against VEEV and perhaps ot

144 e of virulent revertant viruses in some live-attenuated vaccines, disease from vaccination is rare.

145 hus far, the goal of developing a safe, live attenuated vaccine effective after a single dose has rem

146 Thus, multivalent live-attenuated vaccines elicit multifactorial protective imm

147 Isolation frequency was lowest among live attenuated vaccine failures, a reflection of lower speci

148 immune response and may have value as a live attenuated vaccine for aquaculture.

149 We developed an experimental live-attenuated vaccine for direct inoculation of the respira

150 reviously reported that an experimental live attenuated vaccine for equine infectious anemia virus (E

151 Development of a live attenuated vaccine for human NoV has not been possible b

152 Development of an attenuated vaccine for HuNoV has been hampered by the in

153 is an approach to designing a promising live attenuated vaccine for PEDV.

154 A live-attenuated vaccine for RVF, the MP-12 vaccine, is condit

155 d an opportunity to design a successful live-attenuated vaccine for SARS-CoV and opens avenues for tr

156 herefore, NU14 DeltawaaL is a candidate live-attenuated vaccine for the treatment and prevention of a

157 , indicating the potential of TCRV as a live-attenuated vaccine for the treatment of Argentine hemorr

158 The absolute efficacies of the live attenuated vaccine for these end points were 8% (95% CI,

159 a decade is required for approval of a live, attenuated vaccine for use in humans.

160 approach for the rational design of stable, attenuated vaccines for a wide variety of viruses.

161 as a novel target to rationally design live attenuated vaccines for aMPV and perhaps other paramyxov

162 ding may also enable the development of live attenuated vaccines for both RSV and other members of th

163 approach to produce safe and effective live-attenuated vaccines for DENV and other insect-borne viru

164 Two live-attenuated vaccines for gastroenteritis (Rotateq [Merck]

165 the development of safe and efficacious live attenuated vaccines for hMPV and other human paramyxovir

166 as a novel target to rationally design live attenuated vaccines for hMPV and perhaps other paramyxov

167 n rates may become a new strategy to develop attenuated vaccines for humans and animals.

168 ster donor strain for the generation of live attenuated vaccines for humans and livestock.

169 would add an HPV component to existing live attenuated vaccines for measles and typhoid fever.

170 also facilitate the development of new live attenuated vaccines for VSV, and perhaps other NNS RNA v

171 ccine constructs use the E protein in a live attenuated vaccine format, utilizing a backbone derived

172 Among young children, live attenuated vaccine had significantly better efficacy tha

173 CoVs), and the inactivation of nsp16 in live attenuated vaccines has been attempted for several betac

174 Development of live, attenuated vaccines has traditionally relied on empirica

175 Although live-attenuated vaccines have been safely administered to RSV

176 Live, attenuated vaccines have prevented morbidity and mortali

177 ed in various animal lentivirus models, live attenuated vaccines have proven to be the most effective

178 However, the existing live-attenuated vaccines have the potential to revert to viru

179 can be restored by immunization with highly attenuated vaccines.IMPORTANCE Chronic viral infections

180 RSV DeltaSH has been tested as a live attenuated vaccine in humans and cattle, and here we dem

181 s and has the potential to be used as a live-attenuated vaccine in humans.

182 ent Chlamydia trachomatis to serve as a live attenuated vaccine in the genital tract.

183 e serious adverse events than any other live attenuated vaccine in use today.

184 Because concerns exist about the use of live-attenuated vaccines in immunocompromised individuals, a

185 ell activity may increase responses to viral attenuated vaccines in older adults.

186 All eight live attenuated vaccines, including Japanese encephalitis vir

187 vanted inactivated vaccine, but not the live-attenuated vaccine, induced a substantial serum IgG anti

188 ed to further define the nature of the live, attenuated vaccine-induced immunity against Coccidioides

189 Two attenuated vaccines, Ingelvac PRRS MLV and Ingelvac PRRS

190 ogy, including human host-pathogen and live, attenuated vaccine interactions; host and cell type rest

191 ancestral immunogens, because the Env of the attenuated vaccine is a direct ancestor to the variant p

192 e vaccine than the previously developed live attenuated vaccine is needed for combating Francisella t

193 ptive immune response generated to this live attenuated vaccine is regulated by both the presence of

194 A live attenuated vaccine is the most promising vaccine strateg

195 reassortant (ML29) is a LASV candidate live-attenuated vaccine (LAV) that has shown promising result

196 dmonston-Zagreb has long been used as a live-attenuated vaccine (LAV) to protect against measles, not

197 Implementation of live-attenuated vaccines (LAV) will represent a major step in

198 Live-attenuated vaccines (LAVs) are the most advanced vaccine

199 RSV live-attenuated vaccines (LAVs) have a history of safe testin

200 Vaccination with live attenuated vaccines (LAVs) is an effective way for preve

201 Implementation of live-attenuated vaccines (LAVs) will represent a major step t

202 enge in a goat model as compared to the live attenuated vaccine MAP316F.

203 regulated immune system, and/or exposure to attenuated vaccines may enhance trained immunity to limi

204 unity in individuals unable to receive live, attenuated vaccines may have employment implications.

205 Attenuated vaccines may therefore lack sufficient innate

206 Successful live attenuated vaccines mimic natural exposure to pathogens

207 Boosting T cell-mediated immunity by live attenuated vaccine Mycobacterium bovis bacillus Calmette

208 s included a chimeric H8/1, intranasal, live-attenuated vaccine on day 1 followed by a non-adjuvanted

209 V and to explore its potential use as a live-attenuated vaccine or a vaccine vector for the treatment

210 of TCRV and also its potential use as a live-attenuated vaccine or a vaccine vector for the treatment

211 Implementation of TCRV as a live-attenuated vaccine or a vaccine vector would be facilita

212 nd safety concerns regarding the use of live attenuated vaccines or potent adjuvants in this populati

213 enaviruses, for their implementation as live-attenuated vaccines or vaccine vectors.IMPORTANCE To dat

214 The multivalent live-attenuated vaccines overcame prior problems involving im

215 pening the possibility for its use as a live-attenuated vaccine platform for ZIKV and other clinicall

216 report the development of a recombinant live-attenuated vaccine platform strain that retains the pote

217 As modified mRNA and live-attenuated vaccine platforms can restrict in utero trans

218 l NS1 protein have emerged as promising live attenuated vaccine platforms.

219 ovel technology to sufficiently deliver live attenuated vaccine powders into the skin.

220 Live-attenuated vaccines present safety challenges, and prote

221 valent rotavirus vaccine (RV5), a live, oral attenuated vaccine, prevented 98% of severe rotavirus di

222 Both attenuated vaccines produced an approximately tenfold lo

223 Although a live-attenuated vaccine protects against MV, vaccination effi

224 nza A (H3N2), 90% of placebo and 87% of live attenuated vaccine recipients but only 23% of inactivate

225 ymphocytes after immune activation with live attenuated vaccines remain poorly characterized.

226 Live-attenuated vaccines represent an attractive immunization

227 ected: 18 and 12 peptides for the killed and attenuated vaccines, respectively.

228 f the risks and benefits indicates that live attenuated vaccine should be a highly effective, safe va

229 The use of live attenuated vaccines should be limited to specific situat

230 Finally, using the mutant as a live-attenuated vaccine showed significant promise for possib

231 s of JUNV have been documented, and a highly attenuated vaccine strain (Candid #1) was generated and

232 igen polymerase) deletion mutant of Ft. live attenuated vaccine strain (Ft.LVS), designated Ft.LVS::D

233 Whereas an F. tularensis live, attenuated vaccine strain (LVS) is the basis of an inves

234 llei Deltaasd mutant may be a promising live attenuated vaccine strain and a biosafe strain for consi

235 some success in animal models, including an attenuated vaccine strain based on an isolate from La Re

236 otection against plague, we developed a live-attenuated vaccine strain by deleting the Braun lipoprot

237 The live attenuated vaccine strain Candid #1 (Can) is approved fo

238 on, DeltaP(rfaH178), was introduced into the attenuated vaccine strain chi9241 (DeltapabA DeltapabB D

239 the highly pathogenic Brescia strain and the attenuated vaccine strain CS were constructed and evalua

240 In the context of an attenuated vaccine strain delivering the pneumococcal an

241 ptomic analysis of the M. gallisepticum live attenuated vaccine strain F and the virulent strain R(lo

242 Two strains were evaluated: the attenuated vaccine strain LaSota (NDV-LS) that replicate

243 Importantly, both the attenuated vaccine strain MP12 and the fully virulent st

244 virulent Mycobacterium tuberculosis with the attenuated vaccine strain Mycobacterium bovis bacillus C

245 rensis organisms were comparable to the live attenuated vaccine strain of Francisella tularensis subs

246 Candid#1 (Cd1) is an attenuated vaccine strain of Junin virus, the causative

247 ity of the glycoprotein of the Candid#1 live-attenuated vaccine strain of JUNV in MACV replication an

248 c-resistance markers in a single recombinant attenuated vaccine strain of Salmonella enterica serotyp

249 We used the live attenuated vaccine strain YFV-17D, which contains many m

250 (cryo-EM), we determined the structure of an attenuated vaccine strain, TC-83, of VEEV to 4.4 A resol

251 transformant could serve as a nonrevertible, attenuated vaccine strain.

252 nd livers than SL3261, the aroA mutant, live attenuated vaccine strain.

253 reverse genetics, a set of experimental live attenuated vaccine strains based on recombinant H5N1 inf

254 Prototype attenuated vaccine strains CVD 1921 and CVD 1941, derive

255 Obtaining stably attenuated vaccine strains has traditionally been an emp

256 We have previously shown that attenuated vaccine strains of measles virus have potent

257 ghout the poliovirus genome yielded the live attenuated vaccine strains of poliovirus.

258 xpression systems and designing new types of attenuated vaccine strains of VEEV and EEEV.

259 strains of Salmonella may be useful as live attenuated vaccine strains or as vehicles for heterologo

260 uld be harnessed for the development of live-attenuated vaccine strains to combat HFAs.

261 Live attenuated vaccine strains, such as type I nonreplicatin

262 engineered polymerases might serve as live, attenuated vaccine strains.

263 host and warrant further development as live-attenuated vaccine strains.

264 nd a strong proinflammatory reaction to live attenuated vaccine strains.

265 ght be used to reduce reactogenicity of live attenuated vaccine strains.

266 he risk of vaccine-induced disease with live-attenuated vaccines strongly limits their use.

267 Live attenuated vaccines such as SIV with a deleted nef gene

268 DENV or vaccination with tetravalent dengue attenuated vaccines (TDLAV) recognize ZIKV-derived pepti

269 ed influenza in the group that received live attenuated vaccine than in the group that received inact

270 stration of dose 1 was more common with live attenuated vaccine than with inactivated vaccine, primar

271 We describe a live-attenuated vaccine that is safe and efficacious in preve

272 ribe the first genetically engineered, live, attenuated vaccine that protects both BALB/c and C57BL/6

273 has resulted in the development of two live, attenuated vaccines that are now licensed in many countr

274 might be deleted for the development of live attenuated vaccines that would be safer to use in situat

275 didates demonstrate the potential for a live attenuated vaccine to protect against disease caused by

276 venging host iron and have been used in live-attenuated vaccines to combat plague epidemics.

277 nstitutes of Health (NIH) has developed live attenuated vaccines to each of the 4 serotypes of dengue

278 Yersinia species have been utilized as live attenuated vaccines to prime protective immunity against

279 Live-attenuated vaccines typically offer rapid and durable im

280 nant Sendai virus (rSeV) was used as a live, attenuated vaccine vector for intranasal inoculation and

281 ting the feasibility of using TCRV as a live-attenuated vaccine vector for the treatment of JUNV and

282 of heterologous flavivirus species as a live attenuated vaccine vector is not likely to generate opti

283 Live attenuated vaccine vectors based on recombinant vesicula

284 othesized that persistent replication of the attenuated vaccine virus modulates inflammatory response

285 Attenuated vaccine viruses can be used to investigate th

286 tive of restricted viral replication of live attenuated vaccine viruses in humans.

287 ains unclear whether the replication of live attenuated vaccine viruses will be similarly enhanced wh

288 tenuation and host-range restriction of live attenuated vaccine viruses.

289 However, the live attenuated vaccine was found to be ineffective among chi

290 ve (95% CI, 47 to 70; P<0.001), and the live attenuated vaccine was not observed to be effective (vac

291 stalk and catalytic domains of NA as a live attenuated vaccine was shown to confer a strong IAV-spec

292 The efficacy of the live attenuated vaccine was slightly less than that of the in

293 16-2017 A(H1N1)pdm09 strain used in the live attenuated vaccine was unchanged from 2015-2016, the Adv

294 The live-attenuated vaccine was used to assess the impact of the

295 The absolute efficacies of the live attenuated vaccine were 57% (95% CI, -3 to 82), 48% (95%

296 and human infections, new candidate H5 live attenuated vaccines were developed by using two differen

297 ion were higher among the recipients of live attenuated vaccine who were 6 to 11 months of age (6.1%)

298 fer a general approach to the development of attenuated vaccines with well-defined antigenicities and

299 ine and 29% (95% CI, -14 to 55) for the live attenuated vaccine, with a relative efficacy of 60% (95%

300 A single intranasal administration of live attenuated vaccine without adjuvant was sufficient to in